Genome Biol:乳腺癌中DNA甲基化和拷贝数改变调控miRNA异常表达

2013-11-26 MedSci MedSci原创

   挪威奥斯陆大学等机构的研究人员对乳腺癌队列人群进行分析,揭示了DNA甲基化和拷贝数改变对microRNA表达的影响,从而为乳腺癌中miRNA失调背后的机制提供了新证据。这项研究成果于11月20日发表在Genome Biology上。   microRNA(miRNA)是一类小的非编码RNA分子,它通过控制mRNA稳定性和翻译而在转录后水平上调控基因表达。之前的研究

   挪威奥斯陆大学等机构的研究人员对乳腺癌队列人群进行分析,揭示了DNA甲基化和拷贝数改变对microRNA表达的影响,从而为乳腺癌中miRNA失调背后的机制提供了新证据。这项研究成果于11月20日发表在Genome Biology上。

  microRNA(miRNA)是一类小的非编码RNA分子,它通过控制mRNA稳定性和翻译而在转录后水平上调控基因表达。之前的研究发现,miRNA在癌症中往往异常表达。在乳腺癌中,miRNA表达的改变与雌激素受体(ER)信号通路、增殖和转移相关联。然而,miRNA表达异常的潜在机制还不太清楚,可能的原因有DNA拷贝数改变、突变、表观遗传改变等。

  为了了解乳腺癌中拷贝数和甲基化对miRNA表达的影响,奥斯陆大学K.G. Jebsen乳腺癌研究中心的Vessela N Kristensen领导的研究小组整合了全基因组的DNA甲基化、拷贝数和miRNA表达,以鉴定miRNA失调背后的遗传机制。

  研究人员利用安捷伦的8x15k miRNA芯片,开展了89个原发性乳腺癌样本的miRNA表达谱分析。DNA甲基化分析使用的是Illumina的Infinium HumanMethylation450 BeadChip芯片,而DNA拷贝数分析则用的是Illumina Human-1 109k BeadChip SNP芯片。通过这一系列分析,他们鉴定出70个miRNA,其表达与拷贝数或甲基化的改变相关,或与两者都相关。这些miRNA代表了5个miRNA家 族。有趣的是,这些家族的成员编码在不同的染色体上,在甲基化不足或甲基化过度时互补改变。

  在随后的验证研究中,研究人员分析了另123名乳腺癌患者的miRNA表达和拷贝数数据。他们发现,在这70个miRNA中,41个的表达变化模式经 过确认。之后,研究人员在三个乳腺癌细胞系中开展了体外功能实验,用miRNA模拟物来评估其功能意义。他们发现了4个miRNA(miR-21-3p、 miR-148b-3p、miR-151a-5p和let-7e-3p),其中let-7e-3p在肿瘤中与甲基化不足相关,它诱导凋亡并降低细胞活力, 而let-7e-3p低表达与预后不良有关。其他三个miRNA的过表达与拷贝数增加相关,会增加乳腺癌细胞系的增殖。此外,miR-151a-5p提高 了磷酸化AKT蛋白的水平。

  作者认为,他们的数据为乳腺癌中miRNA失调背后的机制提供了新证据。这项研究加深了人们对甲基化和拷贝数改变如何影响miRNA表达的了解。而miRNA家族成员的冗余编码增添了复杂性,在研究miRNA功能时应当考虑。

原始出处:

Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN. Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors.Genome Biol. 2013 Nov 20;14(11):R126.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983895, encodeId=fe31198389590, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue Sep 23 10:16:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766848, encodeId=d8a11e66848bf, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Apr 02 06:16:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930385, encodeId=420e1930385f1, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jan 03 01:16:00 CST 2014, time=2014-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916993, encodeId=b74b1916993e3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 05 12:16:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312256, encodeId=37c5131225663, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Nov 28 14:16:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983895, encodeId=fe31198389590, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue Sep 23 10:16:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766848, encodeId=d8a11e66848bf, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Apr 02 06:16:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930385, encodeId=420e1930385f1, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jan 03 01:16:00 CST 2014, time=2014-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916993, encodeId=b74b1916993e3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 05 12:16:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312256, encodeId=37c5131225663, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Nov 28 14:16:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983895, encodeId=fe31198389590, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue Sep 23 10:16:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766848, encodeId=d8a11e66848bf, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Apr 02 06:16:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930385, encodeId=420e1930385f1, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jan 03 01:16:00 CST 2014, time=2014-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916993, encodeId=b74b1916993e3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 05 12:16:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312256, encodeId=37c5131225663, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Nov 28 14:16:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
    2014-01-03 smallant2002
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983895, encodeId=fe31198389590, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue Sep 23 10:16:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766848, encodeId=d8a11e66848bf, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Apr 02 06:16:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930385, encodeId=420e1930385f1, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jan 03 01:16:00 CST 2014, time=2014-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916993, encodeId=b74b1916993e3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 05 12:16:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312256, encodeId=37c5131225663, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Nov 28 14:16:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
    2014-05-05 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1983895, encodeId=fe31198389590, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue Sep 23 10:16:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766848, encodeId=d8a11e66848bf, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Apr 02 06:16:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930385, encodeId=420e1930385f1, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Jan 03 01:16:00 CST 2014, time=2014-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916993, encodeId=b74b1916993e3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 05 12:16:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312256, encodeId=37c5131225663, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Thu Nov 28 14:16:00 CST 2013, time=2013-11-28, status=1, ipAttribution=)]
    2013-11-28 Homburg

相关资讯

Biol Reprod:母亲糖尿病能削弱卵母细胞印迹基因的甲基化

科研人员首次证明了没有得到良好控制的母亲糖尿病能对母亲印迹基因Peg3的甲基化产生不良影响,这对后代发育受到损害有贡献。 此前的研究已经表明,糖尿病母亲的后代表现出了更高的畸形和死胎的发生率,即便是把一个单细胞胚胎从糖尿病母亲移植到非糖尿病母亲体内的时候也是如此。糖尿病母亲的卵母细胞倾向于表现出葡萄糖代谢减少,卵丘细胞和卵母细胞之间的通信被削弱,线粒体失灵,以及排卵率下降,所有这些都可以追溯到胚

BJC:CACNA2D3基因甲基化可预测乳腺癌扩散风险

在一项新研究中,给一个癌基因加上一种分子“便利贴(post-it note)”能够预测患者乳腺癌扩散的风险。 来自英国伦敦帝国学院(Imperial College London)的英国癌症研究中心研究人员证实CACNA2D3基因上高水平的被称作甲基化的分子修饰与乳腺癌患者体内这种疾病的扩散相关联。2012年7月10日,相关研究成果发表在British Journal of Cancer期刊上。

Science:甲基修饰抑制TLR13识别23S rRNA引发细菌耐药

7月19日,Science在线报道,TLR13受体可识别一类保守的23S核糖体RNA序列,以及一种围绕该相互作用的细菌耐药机制。 保护宿主免受感染的机制依赖于识别受体,如Toll样受体(TLRs),以与生俱来的模式识别病原体。 本研究证实,在小鼠体内,孤儿受体TLR13识别一个细菌内保守的23S核糖体RNA(rRNA)序列。该序列是大环内酯类,林肯酰胺以及链霉杀阳菌素类(MLS)抗生素(包括红

2013年诺贝尔奖预测:甲基化发现者可能获奖

离宣布2013年诺贝尔奖的获奖者名单只有一个多星期了。日前,汤森路透宣布了今年“汤森路透引文桂冠奖”的得奖名单,用以预测哪些成果出众的获奖 者有望夺得诺贝尔奖。汤森路透利用他们专有的“Web of Science™”研究与引用数据库中的数据分析可能获得诺贝尔化学奖、物理学奖、生理学或医学奖,以及经济学奖的研究者。   “科学研究的引用情况能够反映研究的影响力,”汤森路透学术与科学研

Science:一幅脑内的甲基化图谱

我们基因的表达可能会受到我们DNA上的特定标记的影响,例如那些通过对特定核苷酸碱基对的甲基化而被赋予的标记——这一过程被称为表观遗传学过程。科学家们现在提出了一个详细的图谱用以阐释在发育中的哺乳动物大脑中的甲基化如何随着时间的推移而变化。在我们很小的时候及在我们的神经环路正在成形时,DNA甲基化会发生在我们大脑的神经元中;事实上,甲基化被认为与脑发育、学习及记忆等方面有关联。与此同时,尽管人们对发

PLoS Medicine:子宫内膜癌可能与HAND2甲基化有关

来自英国伦敦大学学院妇女癌症部的研究人员在11月12日的PLOS Medicine杂志上发表了一项最新研究:发现HAND2基因是子宫内膜癌中的一种差异甲基化热点,这个基因的表观遗传学修饰在子宫内膜癌的发展中起着关键的作用。 作为一种能够引起全球13%死亡人数的疾病,癌症能够在人体的任何地方发生,但是所有癌症都有这样的特征:不受控制的细胞生长和细胞分化减少。遗传改变——在特定基因中的核苷酸序列的变